[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Limoges\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":688},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,50,81,108,130,158,185,213,235,261,293,320,346,369,400,423,449,478,502,528,557,588,614,639,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644961","interest-of-the-negative-predictive-value-of-integrons-in-the-reduction-of-large-broad-spectrum-antibiotics-consumption-for-urinary-tract-infections-100644961",false,"NCT07675018","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS: a Randomized Trial","INVICTUS","Inclusion Criteria:\n\n* Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;\n* Diagnosis of non-severe (qSOFA \\\u003C 2) urinary tract infection coupled with fever ≥ 38°C or \\\u003C 36°C\n* Presence of bacteria in the fresh urine sample and\u002For GNB on the Gram stain\n* Empirical parenteral antibiotic therapy required; Hospitalization required;\n* Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Neutropenia (absolute neutrophil count \\\u003C 500 \u002F mm3)\n* Severe UTI with sepsis (qSOFA ≥ 2) or septic shock\n* Urinary derivation required (ureteral catheter\u002Fper-cutaneous nephrostomy) except for simple urinary catheterization\n* Known allergy to β-lactams\n* Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months\n* Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem\n* Not affiliated to Social Security","ALL","18 Years",{"count":21,"type":22},204,"ESTIMATED","INTERVENTIONAL",[25],"NA","Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\\\u003C2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.",[28,29,30,31],"Drug Resistance, Microbial","Biomarkers","Urinary Tract Infections (UTI's)","Antibacterial Agents",[33,34,35,36],"Integron","Antimicrobial Stewardship","Antimicrobial Resistance","Urinary Tract Infections","NOT_YET_RECRUITING","2026-06-29",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":22},"2026-09-15",{"date":45,"type":22},"2028-09-21",{"name":47,"class":48},"University Hospital, Limoges","OTHER",7,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100618413","apparent-diffusion-coefficient-of-the-intervertebral-disc-in-children-pilot-study-100618413","NCT07331298","Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study","CADDIE","Inclusion Criteria:\n\n* age: patients between 8 and 16 years old\n* Children undergoing magnetic resonance imaging of the lumbar or spinal region as part of their routine care\n* Scoliotic: spinal deformity characterized by a hump on clinical examination and a radiological deformation in the coronal plane greater than 10 ° with no etiology found (idiopathic)\n* Healthy: no hump on clinical examination, walking patients (level 1 and 2 of the global motor function classification system)\n\nExclusion Criteria:\n\n* existence of medullary and vertebral pathology other than scoliosis, history of disc or vertebral infection (spondylo-discitis) on examination, neuro-ectodermal pathology\n* behavioral disturbances incompatible with the performance of the magnetic resonance imaging examination.\n* Refusal of participation.\n* Thoracic scoliosis","8 Years","16 Years",{"count":60,"type":22},60,"30 Days","OBSERVATIONAL","The pathophysiology of adolescent idiopathic scoliosis is unknown. This pathology develops from 10-11 years of age and progresses until skeletal maturity, or even adulthood for the most severe forms.\n\nCurrent knowledge is limited as to its origin on the one hand and the evolutionary nature of scoliosis on the other.\n\nThe mechanical parameters of the intervertebral disc are incompletely known from the deep location of this organ, its fragile nature in vivo and its susceptibility to desiccation during ex-vivo analysis.\n\nTo complete our knowledge of the mechanical parameters of the intervertebral disc of scoliotic and non-scoliotic children, we are proposing an in vivo, non-invasive and non-irradiating study carried out in children who are the main target of this pathology.\n\nThe objective of this work is to characterize the diffusion parameters (apparent diffusion coefficient ADC) of the intervertebral disc in vivo, in a non-invasive and non-irradiating manner by magnetic resonance imaging in children and adolescents. As this measurement has not been carried out in children and adolescents, we want to perform these MRI scans in children free from scoliosis and carriers of scoliosis.",[65],"Scoliosis Idiopathic",[67,68,69,70],"apparent diffusion coeficient","intervertebral disc","scoliosis","child","RECRUITING","2026-06-25",{"date":74,"type":41},"2026-06-26",{"date":76,"type":41},"2026-01-05",{"date":78,"type":22},"2028-04-01",{"name":47,"class":48},2,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":88,"minAge":19,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100457503","childhood-traumas-in-obese-women-association-with-deregulation-of-the-glucocorticoid-axis-and-inflammatory-state-100457503","NCT05237440","Childhood Traumas in Obese Women: Association With Deregulation of the Glucocorticoid Axis and Inflammatory State.","OBEVIE","Inclusion Criteria:\n\n* ≥18 years female BMI≥30kg\u002Fm2\n\nExclusion Criteria:\n\n1. History of bariatric surgery\n2. Any condition or pathology that may influence the corticotropic axis or that may modify the excretion or dosage of cortisol:\n\n   * pregnancy, breastfeeding\n   * hepatocellular insufficiency,\n   * severe heart failure,\n   * mild\u002Fmoderate acute heart failure,\n   * any psychological disorder not stabilised for at least one year\n   * alcohol or drug dependence, not weaned for at least one year\n   * neoplasm under treatment\n3. Current infectious disease or a history of autoimmune disease (except autoimmune hypothyroidism), inflammatory disease and\u002For neurodegenerative disease\n4. Presence of an adrenal adenoma or any known or suspected clinical adrenal or corticotropic disorder\n5. Subjects with a positive diagnosis of hypercorticism or suspected hypercorticism will also be excluded: 8-hour plasma cortisol after Dexamethasone suppression test (DST) (1 mg dexamethasone taken orally at midnight the previous day) greater than 1.8 microg\u002F100 ml (50 nmol\u002Fl)\n6. antidepressant and neuroleptic treatment, benzodiazepine treatment\n7. treatment(s) likely to modify the exploration of the corticotropic axis: systemic or local corticosteroid therapy or glucocorticoid infiltration for less than 6 months\n8. current use of anti-inflammatory drugs or antibiotics\n9. Shift worker","FEMALE",{"count":90,"type":22},102,[25],"We postulate that childhood traumas are associated with deregulation of the glucocorticoid axis and the inflammatory system in obese women. The main objective of the study is to compare the salivary cortisol awaking response in obese women according to the presence of childhood trauma (assessed using the Childhood Trauma Questionnaire, CTQ).",[94],"Obesity",[96,97,98,99,100],"obesity","childhood trauma","hypothalamic-pituitary-adrenal axis","inflammation","metabolic syndrome",{"date":74,"type":41},{"date":103,"type":41},"2022-04-13",{"date":105,"type":22},"2027-05-13",{"name":47,"class":48},1,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100362289","optimizing-long-term-survival-in-organ-transplantation-from-physiopathology-to-optimized-patient-management-100362289","NCT03997253","Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management","BIOSUPORT","Inclusion Criteria:\n\n* Male or female over 18 (no age limit)\n* affiliated to a social security organization\n* Recipient (s) of a kidney, liver or heart transplant\n* followed by at least one of the FHU SUPORT centers (Tours, Poitiers, Limoges, Rennes)\n* having given informed consent to participate in the cohort.\n\nExclusion Criteria:\n\n* Patient unable to understand the information given by the investigator\n* People under the protection of justice",{"count":116,"type":22},430,[25],"Increased indications for transplantation continue to worsen the shortage of organs and need the extension of graft sampling criteria and the search for new potential sources of organs. Despite undeniable success in the short term, due to major advances in surgery, medicine and research, transplant recipients continue to face the risk of chronic rejection and long-term complications.\n\nThe University Hospital Federation \"FHU SUPORT\" was created to optimize the chances of success of the organ transplant and improve the quality of life of the transplanted patient. FHU SUPORT 's ambition is based on a translational strategy that presents two priority areas:\n\nAxis 1: Optimization, evaluation, conditioning of the donor, graft, recipient Axis 2: Personalized follow-up of the transplanted patient in the short and long term Identifying factors for long-term graft and patient survival through translational research from a common cohort and biological collection will predict transplant rejection, prolong graft function, or improve the patient's care.",[120],"Organ Transplantation",[122],"organ transplantation, graft, biological collection.",{"date":38,"type":41},{"date":125,"type":41},"2020-12-21",{"date":127,"type":22},"2027-06",{"name":47,"class":48},4,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":107},"100520211","tolerance-study-of-robotic-assisted-virtual-reality-walking-rehabilitation-for-non-walking-stroke-patients-100520211","NCT06053619","Tolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients","RAVIS","Inclusion Criteria:\n\n* Hemiparesis following a first ischemic or hemorrhagic stroke;\n* subacute phase (15 days to 6 months);\n* Aged 35 to 75 years;\n* Non-walking subject (unable to walk 3 x 10 meters without human assistance or Functional Ambulation Classification ≤ 2);\n* Benefiting from robot-assisted walking rehabilitation in the readaptation and physical medecin department of the Limoges University Hospital;\n* Having the cognitive abilities to understand and follow simple verbal instructions (MMSE \\\u003C 24 or BDAE \\\u003C 2)\n* Be able to give informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Have neurological and psychiatric conditions, other than stroke;\n* Conditions contraindicating the use of virtual reality (e.g., epileptic disorders, major cerebellar syndrome).\n* Inability to evolve in a virtual environment (MSSQ-Short \\> 26)\n* Patient with acute cardiovascular and respiratory disorders;\n* Patient who is subject to a legal protection measure or who is unable to give consent;\n* Person deprived of liberty\n* Person with high VR experience during the 5 years before stroke\n* pregnant woman, breastfeeding woman","35 Years","75 Years",{"count":140,"type":22},30,[25],"The primary objective of this study is to evaluate the tolerance of the use of immersive virtual reality (VR) during robotic walking rehabilitation sessions by Gait Trainer (GT) in post-stroke patients.\n\nSecondary objectives aim to evaluate the motivation to participate in VR sessions compared to conventional sessions, the participants' sense of presence within the virtual environment, and the usability of the rehabilitation device created. Finally, we will report the actual walking time and number of steps stroke patients take in VR sessions and conventional sessions.",[144,145],"Stroke","Central Nervous System Diseases",[144,147,148,149,150],"Virtual Reality","Stroke Rehabilitation","Robotic","Gait Trainer","2026-06-24",{"date":72,"type":41},{"date":154,"type":41},"2023-11-20",{"date":156,"type":22},"2027-03-11",{"name":47,"class":48},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":107},"100500391","phase-2-the-pento-protocol-in-medication-related-osteonecrosis-of-the-jaw-100500391","NCT05795647","The PENTO Protocol in Medication-related Osteonecrosis of the Jaw","PENTO","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Current or past treatment with bisphosphonates (oral or IV) and\u002For targeted therapies (denosumab, bevacizumab)\n* Signs and symptoms for more than 8S with confirmation that the signs and symptoms are not of dental origin\n* AAOMS Stage 2 MRONJ\n* For patients of childbearing age, effective contraception is required\n\nExclusion Criteria:\n\n* History of head or neck radiotherapy or maxilla metastases\n* Patients who have received treatment in the past (PENTO or PENTOCLO protocol)\n* Patients who have undergone surgery for their MRONJ within the last 3 months\n* Pregnant or wishing to be pregnant, breastfeeding\n* Patient under palliative care\n* Patient with hypersensitivity to pentoxifylline or tocopherol or to an excipient\n* History of hypersensitivity reaction to penicillins, cephalosporins, or other beta-lactams (and clindamycin or lincomycin if applicable) or excipient of amoxicillin-a. clavulanic or clindamycin\n* History of jaundice\u002Fhepatic injury related to amoxicillin\u002Fclavulanic acid\n* Patient taking oral anticoagulants, or with a history of major bleeding or bleeding disorders\n* Patient taking platelet aggregation inhibitor, theophylline or aminophylline\n* Patient taking methotrexate, probenecid, mycophenolate mofetil, myorelaxant drugs, macrolide or streptogramin antibiotics\n* Patients with hepatic failure or renal failure (Cl \\\u003C 30 mL\u002Fmin),\n* Patient with hypotension (SBP \\\u003C 90 mmHg)\n* Refusal to participate in the study\n* Patient participating in other interventional research that may interfere with the conduct of this research\n* Patient unable to understand the protocol\n* Patient under curatorship or guardianship",{"count":166,"type":22},17,[168],"PHASE2","Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.",[171],"Medication-related Osteonecrosis of the Jaw (MRONJ)",[173,174,175,176,177],"MRONJ","pentoxifylline","tocophérol","bone exposure","renutrition","2026-06-23",{"date":151,"type":41},{"date":181,"type":41},"2024-02-29",{"date":183,"type":22},"2028-04-07",{"name":47,"class":48},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":49},"100527444","french-german-cohort-study-to-determine-factors-associated-with-weight-loss-in-amyotrophic-lateral-sclerosis-100527444","NCT06147843","French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis","FG-CoALS","Inclusion Criteria:\n\n* Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis.\n* Incident ALS cases identified and followed-up in the participant ALS \\& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany.\n* Patients who signed the informed consent form.\n* Adults aged \\>18 years old\n\nExclusion Criteria:\n\n* Inability to understand the requirements of the protocol.\n* Cognitive inability to sign and comprehend the informed consent form.\n* Patients who will not accept Riluzole therapy during their follow-up.",{"count":193,"type":22},1000,[25],"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.\n\nParticipants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.",[197],"Amyotrophic Lateral Sclerosis",[199,200,201,202,203,204,205],"Amyotrophic lateral sclerosis","Weight Loss","Genetics","Nutrition","Prognosis","Metabolomics","Inflammation","2026-06-19",{"date":151,"type":41},{"date":209,"type":41},"2024-09-17",{"date":211,"type":22},"2029-09-30",{"name":47,"class":48},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":129},"100644254","hemodynamic-impact-of-the-spontaneous-ventilation-test-in-patients-at-risk-of-weaning-pulmonary-oedema-100644254","NCT07666880","Hemodynamic Impact of the Spontaneous Ventilation Test in Patients at Risk of Weaning Pulmonary Oedema","WAPITI 2","Inclusion Criteria:\n\n* Adult patient (\\> 18 years) on invasive mechanical ventilation in the ICU for more than 48 hours\n* In the ventilator weaning phase with a first SBT planned\n* At risk of WIPE: age over 65 years and\u002For any type of heart disease and\u002For chronic respiratory failure and\u002For obesity\n\nExclusion Criteria:\n\n* Patient who has already participated in the study\n* No transthoracic echocardiographic images suitable for analysis\n* Non-sinus rhythm (including pacemaker)\n* Tracheostomy\n* Chronic neuromuscular or neurodegenerative disease\n* Persons deprived of liberty or under legal protection\n* Pregnant or breastfeeding woman",{"count":221,"type":22},88,[25],"Weaning-induced pulmonary edema (WIPE) from the ventilator is a frequent cause of extubation failure or delay, which prolongs the duration of invasive mechanical ventilation and the associated morbidity and mortality. WIPE is a very frequent cause of extubation failure in at-risk patients. A spontaneous breathing trial (SBT) is performed before extubating a patient, either by disconnecting the patient from the ventilator (T-piece SBT) or by setting the ventilator to spontaneous breathing mode with pressure support at 7 cm H2O and zero positive end-expiratory pressure (PS-ZEEP SBT). There is currently no recommendation regarding which SBT modality should be used, particularly in patients at risk of WIPE. The hemodynamic changes induced by the SBT can lead to WIPE, which typically develops within minutes of the SBT onset.\n\nThe hypothesis being tested is that, by altering intrathoracic pressure during the patient's inspiration (negative pressure), the T-piece SBT leads to a greater increase in left ventricular filling pressures compared to the PS-ZEEP SBT.",[225],"Weaning-induced Pulmonary Edema",[227],"Weaning-induced pulmonary edema","2026-06-18",{"date":151,"type":41},{"date":231,"type":22},"2026-08-01",{"date":233,"type":22},"2029-08-07",{"name":47,"class":48},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":137,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":166},"100530021","trial-evaluating-the-rate-of-pneumothorax-in-severe-emphysema-secondary-to-endoscopic-volume-reduction-with-two-stage-zephyr-valves-versus-endoscopic-volume-reduction-with-one-stage-zephyr-valves-100530021","NCT06181357","Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","Randomized Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves","REPEAT","Inclusion Criteria:\n\nPatient able to give informed consent and participate in the study\n\n* Age ≥ 35 years old and ≤ 80 years old at the time of signing the consent\n* Emphysema (homogeneous or heterogeneous) on a recent CT scan (\\\u003C 6 months). Heterogeneous emphysema defined by a difference of at least 15% destruction (threshold 910HU) between two adjacent lobes.\n* Destruction ≥ 50% (threshold 910 HU) of the target lobe on the chest scanner\n* Smoking quit for 3 months\n* Dyspnea ≥ 2 according to the modified Medical Research Council (mMRC) questionnaire)\n* Post-bronchodilator FEV between 15 and 50% theoretical\n* Post-bronchodilator total lung capacity ≥ 100% theoretical and post-bronchodilator residual volume ≥ 175% theoretical\n* Distance traveled during the TM6M ≥ 100m\n* Member of or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Asthma considered as main diagnosis\n* Recurrent exacerbations: (\\>3 over the last year or 2 requiring hospitalization)\n* Myocardial infarction or stroke in the 6 months prior to inclusion\n* Symptoms of heart failure in the 6 months prior to inclusion\n* Chest CT abnormalities: giant bulla (occupying more than a third of the pulmonary field), paraseptal emphysema, pulmonary nodule greater than 0.8cm (not applicable pulmonary nodules known for more than a year and stable), fibrosing interstitial pneumonitis, dilated bronchi\n* Pulmonary tomoscintigraphy:\n\n  * Patients for whom the least perfused lobe is not the one with the highest emphysema destruction score\n  * Patients with homogeneous emphysema for whom the perfusion delta (difference in perfusion between the ipsilateral lung and the treated lobe) is less than 10%\n* Arterial blood gas analysis in ambient air: Hypoxemia in ambient air (PaO2 \\\u003C 45 mmHg). Hypercapnia (PaCO2 \\> 55 mmHg)\n* Echocardiography:\n\n  * Left Ventricular Ejection Function \\\u003C 45%\n  * Systolic pulmonary arterial pressure \\> 45 mmHg\n* History of pneumonectomy, lung surgery homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of pneumothorax homolateral to the lobe targeted for endoscopic lung volume reduction\n* History of endoscopic volume reduction\n* Oral corticosteroid therapy \\> 20 mg\u002Fday within the 4 weeks preceding inclusion\n* Symptomatic bronchial dilatations, bronchial colonization with pseudomonas aeruginosa, multi-resistant bacteria or aspergillus origin\n* Metastatic cancer undergoing treatment or whose treatments ended less than 5 years ago\n* Pregnant or breastfeeding women\n* Nickel allergy\n* Patient under guardianship, curatorship or under judicial protection\n* Participation in another interventional clinical research\n* Any other condition which, in the opinion of the investigator, could interfere with the objective of the study or would cause the subject's participation in the study to be suboptimal, in particular (non-exhaustive list) unweaned alcoholism, substance abuse, non-compliance with usual follow-up visits)\n\nsecondary exclusion criteria:\n\n\\- Evidence of collateral ventilation measured by the Chartis system","80 Years",{"count":245,"type":22},244,[25],"Chronic obstructive pulmonary disease (COPD) affects 3.5 million people and is the third leading cause of death worldwide. Emphysema involves air retention in the lungs and is ultimately responsible for a major deterioration in the quality of life. Available drug treatments have moderate efficacy whereas surgical lung volume reduction can improve exercise capacity when offered to a very selected population but at the cost of significant morbidity and mortality.\n\nEndoscopic Lung Volume reduction with ZEPHYR® valves improves respiratory function at rest, exercise tolerance and quality of life in patients with little or no interlobar collateral ventilation.\n\nIf this technique has therefore proven its effectiveness, it is not devoid of complications and is notably responsible for pneumothorax in 27% of cases. The management of this complication is clearly codified, ranging from patient monitoring to the removal of one or more valves. It is therefore a subject of major concern for multiple reasons: high incidence, lengthening of hospital stay, increase in the overall cost of care, potential loss of benefit for the patient in the event of permanent withdrawal. valves and above all a potentially fatal event.\n\nA new strategy for implanting ZEPHYR® valves in two stages has been developed in Limoges University Hospital. This innovative algorithm has been evaluated in several non-comparative single or multicenter studies. In those studies, pneumothorax' rate secondary to lung volume reduction with endobronchial valves is rated between 4.5 and 12%. The efficacy of the treatment appears to be comparable with the data found in the trials evaluating in which the entire lobe was treated in one procedure. Moreover, despite two procedures, there does not seem to be any increased risk of occurrence of other complications. Finally, the systematic scheduling of a thoracic computed tomography between the two procedures showed that 26.6% of patients presented a reduction in volume greater than 350mL despite incomplete treatment.\n\nThese data seem promising but no direct comparison with standard one-step treatment has ever been conducted so far.",[249],"COPD",[251,252,253,254,249],"Endobronchial Zephyr® valves","Endoscopic lung volume reduction","Pneumothorax","Emphysema",{"date":178,"type":41},{"date":257,"type":41},"2024-05-06",{"date":259,"type":22},"2029-06-06",{"name":47,"class":48},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":270,"conditions":271,"keywords":277,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":107},"100640793","physical-activity-level-at-home-in-cmt1a-patients-wearable-sensor-assessment-100640793","NCT07591779","Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment","Study of the Relationship Between Clinical and Functional Characteristics of Patients With CMT1A Disease and Their Level of Physical Activity at Home Measured Using Portable Electronic Sensors","CMT1A-HOME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Genetically confirmed diagnosis of CMT1A (PMP22 duplication on chromosomal analysis)\n3. Followed at the National Reference Centre for Rare Peripheral Neuropathies (Service de Neurologie, CHU de Limoges) and\u002For having undergone gait analysis at the Quantified Movement Analysis Laboratory (Laboratoire d'AQM), Service de Médecine Physique et de Réadaptation, CHU de Limoges\n4. Ability to walk independently (with or without walking aids)\n5. Informed consent obtained\n6. Affiliated to French social security system\n\nExclusion Criteria:\n\n1. Other associated neurological condition that could independently affect walking or motor activity\n2. Inability to wear the sensor device (skin allergy, sensory intolerance)\n3. Inability to comply with study procedures (cognitive impairment, no fixed domicile)\n4. Participation in another interventional study during the same period\n5. Pregnant or breastfeeding women\n6. Patients under legal protection (guardianship or curatorship)",{"count":60,"type":22},"Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common hereditary peripheral neuropathy, affecting approximately 26,000 patients in France. It presents as chronic and progressive sensorimotor deficits predominantly affecting the distal lower limbs, with onset typically in childhood. There is currently no specific pharmacological treatment; management remains symptomatic.\n\nThis research will:\n\nIn the long run, validated wearable sensors could improve patient follow-up, personalize rehabilitation, and support the design of clinical trials for CMT1A - including trials of the novel \"Nano-Cur\" treatment currently under development.",[272,273,274,275,276],"Charcot-Marie-Tooth Disease, Type IA","Peripheral Neuropathy Hereditary","Motor Activity","Walking, Difficulty","Neuromuscular Diseases",[278,279,280,281,282,283,284],"CMT1A","wearable sensor","actigraphy","physical activity","CMT-FOM","functional assessment","peripheral neuropathy","2026-05-20",{"date":287,"type":41},"2026-05-22",{"date":289,"type":22},"2026-06-01",{"date":291,"type":22},"2027-06-30",{"name":47,"class":48},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":300,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},"100581713","gene-discovery-in-chb-patients-to-identify-unknown-pathways-that-lead-to-b-and-nk-cell-deregulation-100581713","NCT06853886","Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation","LiNKeB2","Inclusion Criteria:\n\n* Male or female, age ≥18 years old\n* HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog\n* Willing and able to provide written informed consent\n* Affiliated with a social securityregimen\n\nHealthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n* Male or female, age between 18 and 80 years\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)\n* Acute hepatitis in the year preceding recruitment\n* Other liver diseases : alcohol, obesity (BMI\\>30), diabetes, metabolic syndrome (dyslipidemia and\u002For known hypertension) - Underlying immunological or cancerous diseases\n* Patient with a disability that prevents him\u002Fher from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship\n* Pregnant or breast-feeding women.\n\nSecondary exclusion criteria:\n\n* A healthy volunteer whose vaccination status does not match that expected on the basis of serological results\n* Positive blood pregnancy test on inclusion\n* Positive HCV, HIV or HDV test in a patient\n* Positive HBV, HCV, HIV or HDV test in a healthy volunteer",true,{"count":302,"type":22},140,[25],"Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.",[306],"Chronic Hepatitis B Virus",[308,309,310,311],"HBV","NK celles","TLR9","B cells","2026-05-19",{"date":285,"type":41},{"date":315,"type":41},"2025-08-12",{"date":317,"type":22},"2028-10-01",{"name":47,"class":48},3,{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":80},"100634564","complementary-and-alternative-medicine-among-patients-with-hematologic-malignancies-in-france-100634564","NCT07541326","Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France","Use of Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France: a Mixed-methods Study","COMPLHEMATO","Inclusion Criteria:\n\n* Patients diagnosed with acute leukemia, lymphoma, or myeloma who are hospitalized and undergoing treatment at any of the study centers, regardless of the stage of the disease.\n* Patients aged 18 years or older.\n* Patients who are literate in French.\n* Patients who have been informed about the study and have provided their consent to participate.\n* Patients covered by health insurance.\n\nExclusion Criteria:\n\n* Patients with neurocognitive disorders or severe psychiatric conditions.\n* Patients in the terminal stage of the disease.\n* Patients under legal protection measures, such as guardianship or curatorship.\n* Patients participating in an interventional study on the effectiveness of CAM.",{"count":329,"type":22},85,[25],"Integrative medicine promotes the incorporation of elements from complementary and alternative medicines (CAM) into patient care. These approaches are defined as treatments that are not routinely part of conventional medical care (1). CAM practices include osteopathy, acupuncture, aromatherapy, naturopathy, and various energy-based techniques, although their efficacy is not always well-established. Nevertheless, a meta-analysis on the use of CAM in the context of cancer reported a 40% prevalence of use in 2012 (2). Subsequently, a study conducted in France in 2015 revealed an 83% prevalence of CAM use across all types of cancer, underscoring the interest in these therapies (3). CAM is often employed to alleviate side effects of conventional treatments, such as fatigue, nausea, and vomiting. The 2015 French study primarily focused on solid tumors, with hematological malignancies representing only 2% of the cases, thereby limiting the assessment of CAM use in this context (3). Currently, there is no specific data evaluating the use of CAM among patients with hematological malignancies in France.\n\nHematological malignancies, unlike solid tumors, are characterized by their diffuse nature, making their localization and treatment more challenging for patients to comprehend (4). Additionally, a qualitative study the investigators conducted on the spiritual needs of patients recently diagnosed with hematological malignancies identified CAM as an area of interest. Among the ten patients in the study, seven were using CAM and reported an improvement in their spiritual well-being, which is defined as the ability to integrate the meaning and purpose of life into their health experiences, through relationships with themselves, others, art, nature, or a higher entity. This aspect of CAM utilization was not explored in our previous study on the spiritual needs of patients, particularly in understanding their appeal and the motivations of patients to adopt them.\n\nTherefore, it appears crucial to explore this practice, which is known to be common among healthcare providers. Understanding these complementary care pathways would enable their safety (e.g., avoiding or informing about potential drug interactions) and foster the patient-provider relationship around a topic that is sometimes considered taboo (5). Ultimately, this would contribute to better supporting patients within a holistic care perspective.",[333],"Hematological Malignancies",[335,336,337],"Alternative medicine","complementary medicine","blood disease","2026-04-16",{"date":340,"type":41},"2026-04-21",{"date":342,"type":22},"2026-06-15",{"date":344,"type":22},"2027-12-15",{"name":47,"class":48},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":80},"100594467","phase-4-esmolol-versus-sufentanil-on-the-quality-of-post-cholecystectomy-recovery-laparoscopic-anaesthesia-with-orotracheal-intubation-on-an-outpatient-basis-100594467","NCT07019818","Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intubation on an Outpatient Basis","Esmolol Versus Sufentanil on the Quality of Recovery After Laparoscopic Cholecystectomy During Anaesthesia With Orotracheal Intubation on an Outpatient Basis","ESA","Inclusion Criteria:\n\n* Adult patients\n* ASA I to III\n* Scheduled outpatient cholecystectomy\n* General anesthesia with orotracheal intubation\n* Patient with signed consent\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Patients on beta-blockers\n* Uncontrolled hypertension\n* Contraindication to beta-blockers\n* Hypersensitivity to the active substance or to one of the excipients of sufentanil and esmolol\n* Pre-existing hemodynamic abnormality\n* Intubation planned to be difficult during the anaesthesia consultation\n* Severe obesity (BMI \\> 35 kg\u002Fm2)\n* Pregnant or breast-feeding women\n* Patients deprived of liberty\n* Patients under guardianship",{"count":355,"type":22},120,[357],"PHASE4","There are 120,000 outpatient laparoscopic cholecystectomies with orotracheal intubation per year in France.\n\nSufentanil is the most commonly used morphine during surgery in France, but morphines have harmful effects when administered for surgery. As with other morphine-based analgesics (painkillers), sufentanil can be associated with nausea and vomiting, confusion, itching and addiction.\n\nThere is an approach to anaesthesia which aims to eliminate the use of morphine in order to avoid its side effects, but there is a lack of clinical trials and benchmarks to provide proof of this.\n\nEsmolol is a cardioselective beta-blocker (a substance that acts only on the heart) which also has marketing authorisation for all types of surgery, the most frequent side effects of which are hypotension and bronchospasm.\n\nThese two drugs have different therapeutic properties for a common objective under general anaesthesia, namely the stability of vital parameters (such as pulse, blood pressure, blood oxygenation, etc.) during surgery.\n\nEsmolol disappears very quickly from the body, which could give it an interesting place in outpatient management.\n\nThe hypothesis tested in this study is that the use of Esmolol is an effective alternative to Sufentanil during general anaesthesia for laparoscopic cholecystectomy with orotracheal intubation on the quality of post-operative recovery and pain.\n\nThe aim of this study is to evaluate whether the use of Esmolol is equivalent to the use of Sufentanil in terms of patient comfort, assessed in terms of quality of recovery, after general anaesthesia with orotracheal intubation for laparoscopic cholecystectomy.",[360],"Laparoscopic Cholecystectomy Surgery","2026-04-07",{"date":363,"type":41},"2026-04-13",{"date":365,"type":41},"2025-10-29",{"date":367,"type":22},"2028-01-05",{"name":47,"class":48},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":384,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":399},"100543308","phase-4-evaluation-of-the-benefits-of-administering-immunosuppressive-drugs-as-single-daily-doses-over-the-first-year-after-liver-transplantation-easy-100543308","NCT06354179","Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation","EASY","Inclusion Criteria:\n\n* Recipients of a first liver allograft from a deceased donor\n* Transplanted for less than four weeks at enrolment.\n* Without inter-current progressive life-threatening or graft-threatening disease.\n* Having signed a written informed consent for their participation in the study.\n* Affiliated to, or beneficiary of, a social security regimen\n\nExclusion Criteria:\n\n* Recipients of a split-liver transplantation.\n* Recipients of any transplanted organ other than the liver\n* Patient who has undergone colon resection\n* Patients under legal protection (guardianship, curatorship).\n* Patient presenting any contra-indication to tacrolimus or to MMF according to the summary of product characteristics (SmPC) of ENVARSUS®, ADVAGRAF® and CELLCEPT®.\n* Patients in whom everolimus-based calcineurin inhibitors (CNI) minimization is anticipated\n* Patients treated with HIV or HCV protease inhibitors.\n* Pregnant or lactating women.\n* Women of childbearing potential without any effective contraceptive method (according to the guidelines of CTFG, Clinical Trial Facilitation Group, related to contraception and pregnancy test in clinical trials) or not practicing sexual abstinence.\n* Sexually active men having a female partner, without any effective contraception.\n* Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol.\n* Patients enrolled in another clinical study evaluating drugs or therapeutic strategies potentially interfering with the objectives of the EASY study.",{"count":378,"type":22},162,[357],"World Health Organization considers non-adherence has a strong negative impact on the health of patients with chronic diseases. In transplantation, adherence to immunosuppressive drug regimens associates with late rejection and graft loss making it a critical determinant of patient outcome. The prevalence of non-adherence in transplant patients, including liver transplant patients, can be as high as 40%. Among others, life-long intake and complexity of immunosuppressive regimen make patients prone to non-adherence. For instance, non-adherence is more prevalent among patients with higher numbers of immunosuppressive drugs. One of the most commonly cited causes of non-adherence is forgetfulness and disruptions in routine, with the evening dose of twice daily regimens being the most likely to be affected6. Besides non-adherence, the constraints generated in everyday life by immunosuppression (including timely and regular drug intake) and the complexity of the immunosuppressive regimens represent a burden for the patients and are probably associated with a health-related quality of life deterioration. Therefore, long-term adherence and quality of life after liver transplantation might be improved by using a well-tolerated and easy-to-handle immunosuppressive regimen.\n\nThe immunosuppressive regimen after liver transplantation is in most cases based on different combinations of tacrolimus, mycophenolate mofetil and corticosteroids. While corticosteroids are administered once daily, tacrolimus can be administered either twice-daily (BID) as an immediate-release, or once-daily (QD) as an extended-release formulation. Among once-daily tacrolimus formulations, LCP-tacrolimus (ENVARSUS XR®) is approved for the prevention of transplant rejection in adult liver allograft recipients. It has demonstrated similar outcomes compared to immediate-release tacrolimus BID, in both kidney and liver transplantation. Mycophenolate has only been approved for BID administration, preventing from taking all immunosuppressive drugs once daily. Yet, single daily dosing would probably contribute to better adherence and quality of life in patients receiving a life-long treatment.\n\nAlthough the half-life of mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF) is compatible with once-daily administration, no published randomized clinical study has ever evaluated the efficacy and safety of MMF administered QD.\n\nThe narrow therapeutic index and wide pharmacokinetic variability of tacrolimus and mycophenolate justify individual dose adjustment by means of therapeutic drug monitoring (TDM), in order to minimize the risk of acute rejection and the occurrence of adverse events. For tacrolimus, TDM is generally based on the trough concentration (C0) and sometimes on the area under the concentration-time curve (AUC), while for mycophenolate it should be based on the AUC of MPA. However, the dose adjustment of MMF in liver transplant patients is most of the time performed a posteriori, based on clinical signs of inefficacy of toxicity.\n\nLimited sampling strategies with maximum a posteriori Bayesian estimation have been developed by our team for both molecules in adult liver transplant patients to estimate their AUC, which is considered the best marker of exposure for both. Therefore, tacrolimus AUC0-24h can be estimated by Bayesian estimation using samples collected before administration (C0), 8 (C8h) and 12 (C12h) hours after the administration of ENVARSUS XR®, or 1 and 3 hours after the administration of PROGRAF® and ADVAGRAF®. For mycophenolate, the MPA AUC can be estimated using samples collected 20 min, 1 and 3 hours after MMF administration, by Bayesian estimation.\n\nEven if limited to 2 or 3 blood samples, tacrolimus TDM for ENVARSUS® requires late sampling (12h post-dose). To overcome the necessity of a longer hospital stay, microsampling devices (MSD) such as the Volumetric absorptive microsampling (VAMS®) device (Mitra®) can be used by the patients to take samples themselves, at home. Moreover, they are less invasive than venipuncture and collect low but accurate volumes of blood for analysis.\n\nIn this context, we propose a randomized controlled non-inferiority study to demonstrate that in liver transplant recipients, an immunosuppressive strategy based on single daily doses of LCP-tacrolimus (ENVARSUS XR®) and mycophenolate mofetil (CELLCEPT®) started at M6 post-transplantation is not inferior to XR-tacrolimus (ADVAGRAF®) and MMF administered BID, in terms of incidence of treatment failure (see below) at the end of the first year after transplantation, and to obtain adherence, quality of life and safety data. In order to compare solely MMF QD to MMF BID, patients on ENVARSUS XR® and MMF QD will be compared to a third group of patients receiving ENVARSUS XR® and MMF BID. A direct comparison of efficacy and safety, quality of life, adherence and exposure indices will be performed between ENVARSUS XR® and ADVAGRAF®.",[382,383],"Liver Transplantation","Immunosuppression",[385,386,387,388,389,390],"liver transplantation","immunosuppression","tacrolimus","mycophenolate","adherence","once-daily intake","2026-03-16",{"date":393,"type":41},"2026-03-19",{"date":395,"type":41},"2025-04-15",{"date":397,"type":22},"2028-04-15",{"name":47,"class":48},18,{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":407,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":422},"100378440","a-national-prospective-cohort-of-patients-with-idiopathic-nephrotic-syndrome-beginning-in-childhood-100378440","NCT04207580","A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.","PIN'SNP","Inclusion Criteria:\n\n* Patient under 18 years of age\n* With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018\n* Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology\n* Residing in France\n* Consent signed by parents and patient's agreement to participate (if of age)\n* Affiliated to a social security system.\n\nExclusion Criteria:\n\n* Refusal of the patient or legal representatives to participate in the cohort",{"count":408,"type":22},1180,"Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies.\n\nThe main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.",[411],"Idiopathic Nephrotic Syndrome",[413],"Cohort - Idiopathic nephrotic syndrome - child","2026-03-11",{"date":416,"type":41},"2026-03-13",{"date":418,"type":41},"2020-03-13",{"date":420,"type":22},"2048-01",{"name":47,"class":48},48,{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":4},"100626526","b-lymphocyte-populations-in-the-pulmonary-microenvironment-of-patients-under-mechanical-ventilation-with-or-without-vap-ventilator-associated-pneumonia-100626526","NCT07436780","B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)","Pilot Study Describing B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP (Ventilator-Associated Pneumonia)","OLYMPE","Inclusion Criteria:\n\n* Adult patients (≥18 years old), admitted to intensive care under mechanical ventilation for an estimated duration of at least 5 days.\n\nExclusion Criteria:\n\n* Patients admitted for an infectious pneumonia or presenting with acute respiratory distress syndrome (ARDS). Patients in aplasia (leukocytes \\\u003C 0.5 gigal\u002FL).",{"count":432,"type":22},75,"Diagnosis of VAP relies on a set of non-specific clinical, biological, and imaging criteria.\n\nUnderstanding host-pathogen interactions and the mechanisms of deregulations leading to infection of pulmonary tissue appears essential.\n\nThe aim is to qualitatively describe the B lymphocyte populations present in the pulmonary microenvironment of patients admitted to intensive care and requiring invasive mechanical ventilation",[435],"Ventilator-associated Pneumonia",[437,438,439,440],"ventilator-associated pneumonia","Intensive care medicine","host-pathogen interaction","humoral immunity","2026-02-23",{"date":443,"type":41},"2026-02-27",{"date":445,"type":22},"2026-01-31",{"date":447,"type":22},"2027-07-30",{"name":47,"class":48},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":459,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":80},"100624191","evaluation-of-efficacy-of-coconut-oil-mouth-care-for-non-autonomous-hospitalised-elderly-people-100624191","NCT07406425","Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People.","Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People: a Multicentric Randomised Controlled Trial","COCO-CARE","Inclusion Criteria:\n\n* Patients aged 75 and over\n* Patients hospitalised in geriatric medicine and geriatric SMR departments\n* Patients able to open their mouths for treatment\n* Patients not able to carry out their oral hygiene on their own\n* Patients who have given their written consent (consent of the patient or patient consent accompanied by the designated representative if the patient is unable to give written consent)\n\nExclusion Criteria:\n\n* Patients with a known allergy to coconut\n* Patients requiring medicated mouth care as prescribed by a doctor\n* Patients under guardianship, tutorship or curatorship\n* Confused patients who have had medically diagnosed dehydration for less than 48 hours\n* Patients with swallowing difficulties\n* Patients in the terminal phase of end of life\n\nSecondary exclusion criteria:\n\n* Patients leaving the department between D1 and D8 (whatever the reason for discharge, and including in the event of death)\n* Patients whose condition progresses towards a terminal phase of the end of life between D1 and D8\n* Patients experiencing an allergic reaction to Coconut Oil during the study\n* Patients who may present with dehydration during the study",{"count":458,"type":22},94,[25],"This is a prospective, longitudinal, randomised, open-label, multicentric, interventional, comparative superiority study.\n\nThe main objective is to demonstrate the superiority of oral care with coconut oil on the oral status of elderly people hospitalised in geriatrics, versus oral care with glycerol sticks.",[462,463],"Geriatrics","Oral Health Care",[465,466,467,468,469],"geriatrics","oral health care","elderly","coconut oil","palliative care","2026-02-05",{"date":472,"type":41},"2026-02-12",{"date":474,"type":22},"2026-03-15",{"date":476,"type":22},"2026-10-15",{"name":47,"class":48},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":300,"sex":18,"minAge":138,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":107},"100534314","effects-of-the-cotid-community-occupational-therapist-in-dementia-program-and-usual-occupational-therapy-care-on-recurrence-of-falls-at-12-months-in-elderly-people-with-neurocognitive-disorders-who-had-been-hospitalized-for-falls-after-their-return-home-100534314","NCT06237218","Effects of the COTID (Community Occupational Therapist in Dementia) Program and Usual Occupational Therapy Care on Recurrence of Falls at 12 Months in Elderly People With Neurocognitive Disorders Who Had Been Hospitalized for Falls, After Their Return Home","Effets du Programme COTID (Community Occupational Therapist in Dementia) et d'Une Prise en Soins ergothérapique Habituelle Sur la récidive de Chutes à 12 Mois de Personnes âgées Atteintes de Troubles Neurocognitifs et Ayant été hospitalisées Pour Chute, après Leur Retour à Domicile","ErgoFalls","Inclusion Criteria:\n\n* Male or female, at least 75 years old\n* Living at home (excluding nursing home or long-term care facilities)\n* Hospitalized for fall\n* Presenting major mild to moderate dementia (MMSE \\> 16)\n* Accompanied by a caregiver with sufficient presence to meet study procedures: at investigator's discretion at the investigator's discretion\n* Having given free, informed and written consent signed by the patient\n* Whose caregiver has given free, informed consent written and signed by him\u002Fherself\n* Affiliated or beneficiary of social security\n\nExclusion Criteria:\n\n* With serious, life-threatening pathology(ies) or in palliative care\n* Participating in an educational fall program on the theme of falls, run by an occupational therapist by an occupational therapist\n* Receiving regular occupational therapy treatment on the day of inclusion (day care daily hospitalization)\n* Participating in a clinical research protocol have an impact on the occurrence of a fall (at the investigator's discretion)\n* Not matching with the fall definition from Kellogg's definition of a fall (loss of consciousness, sudden onset of paralysis paralysis or epileptic seizure)\n* Presenting a very significant post-fall syndrome:\n\nscore of 4\u002F4 on the \"Get-up early\" questionnaire\n\n* unable to read or write\n* Participant under legal guardianship (curator, guardian, legal protector)\n* Dementia with rapid neurocognitive degeneration degeneration with frontal and language impairment (at the investigator's discretion).",{"count":487,"type":22},76,[25],"This project will enable optimization of specific carried out by occupationist for older adults discharged from hospital for falls:\n\n* on the environmental dimension at the participant's home\n* on the involvement of the caregiver since they are also involved in the care of the patient\n* on the recurrence of falls and rehospitalizations in order to improve the quality of life by reassuring the elderly person when traveling\n* on limiting loss of autonomy and staying at home. The occupational therapist will entrust the caregiver with a support role. The participant will feel more involved in the participant's care (thus reducing the feeling of helplessness). His actions will allow him to strengthen his sense of competence and will prevent him from physical and psychological exhaustion.",[491],"Nervous System Diseases",[493],"Dementia","2026-01-12",{"date":496,"type":41},"2026-01-14",{"date":498,"type":41},"2024-07-29",{"date":500,"type":22},"2027-03-08",{"name":47,"class":48},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":107},"100615684","identification-and-characterisation-of-iga-with-nephritogenic-potential-in-iga-deposition-nephropathies-rep-igan-100615684","NCT07295808","Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)","Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies","Rep-IgAN","Inclusion Criteria:\n\n* Patients of interest: all patients with IgA nephropathy or rheumatoid purpura aged 18 years or older whose treatment requires a renal biopsy\n* Control patients: all patients with a renal disease other than IgA nephropathy or rheumatoid purpura whose treatment requires a renal biopsy\n\nExclusion Criteria:\n\n* Patient opposition\n* Persons under legal guardianship\n* Persons whose psychological health prevents the collection of non-opposition",{"count":511,"type":22},150,[25],"IgA nephropathy (IgA Nephropathy), or Berger's disease, is the most common form of primary glomerulonephritis. It is a major cause of end-stage renal failure, often leading to dialysis or kidney transplantation. Recurrence is common after transplantation, compromising graft survival. Rheumatoid purpura (or IgA vasculitis) shares a common pathophysiology with IgA N, characterised by mesangial deposits containing IgA-rich immune complexes, but differs in its systemic involvement (skin, joints and digestive system).\n\nIn terms of pathophysiology, the histological signature of these conditions is based on the accumulation of abnormal IgA within the glomerulus. The mechanisms responsible for the nephrotoxicity of these IgA remain partially unclear. In patients with NIgA, several qualitative abnormalities of IgA have been well described, including a glycosylation defect that promotes IgA polymerisation and the emergence of anti-IgA autoantibodies. These immune complexes, found in glomerular deposits, induce a local inflammatory reaction. Experimental work conducted on mouse models developed at the CRIBL laboratory has shown that these abnormalities may be linked to a dysregulation of the immune response, leading to the production of IgA with physicochemical properties that promote their deposition in the kidney.\n\nHowever, the location of nephritogenic IgA-secreting B cells remains poorly understood. Recent data suggest that this production could occur directly within the renal parenchyma, where activated B lymphocytes would locally produce pathogenic IgA. Following on from these observations, our study aims to characterise the immunoglobulin (Ig) repertoires in patients with IgA nephropathy, particularly those from renal lymphoid infiltrates, and to compare them with the repertoires of circulating B cells.\n\nWe hypothesise that certain sequence motifs within the variable domains of IgA, particularly the CDR3 regions, could constitute specific biomarkers of NIgA. Their detection in peripheral blood could enable non-invasive or predictive diagnosis, complementing the renal biopsy that is currently essential.",[515],"Kidney Disease",[517,518,519],"Kidney disease","Immunoglobulin A","Berger's disease","2025-12-08",{"date":522,"type":41},"2025-12-22",{"date":524,"type":41},"2025-06-25",{"date":526,"type":22},"2029-07-25",{"name":47,"class":48},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":556},"100575588","phase-3-prevention-of-secondary-infections-by-interferon-gamma-in-icu-acquired-sustained-immune-suppression-100575588","NCT06774235","Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression","Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression: a Randomized Trial","PLATINIUM","Inclusion Criteria:\n\n* Adult patient hospitalized in the ICU for at least 1 week\n* Expected length of stay in the ICU greater than 10 days at screening\n* At least 1 episode of multiple organ failure, defined as a SOFA ≥ 6 (excluding the respiratory component when related to a neurological failure), during the first 1 week of ICU hospitalization\n* Immunosuppression defined as an mHLA-DR \\\u003C 8000 Ab\u002Fc and a lymphopenia \\\u003C 1000\u002Fmm3 within a 96 hours time window\n* Patient or the legal representative giving consent must be able to understand the trial in its entirety\n* Patient affiliated to the social security system\n* For female participants of childbearing potential, agreement to use dual methods of contraception until Day 90\n* For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 90.\n\nExclusion Criteria:\n\n* Uncontrolled secondary infections ongoing at the time of screening\n* Participation in another research clinical trial within 30 days\n* Chemotherapy \u002F radiation therapy within the last 6 weeks\n* Apache II ≥ 30 at screening\n* History of autoimmune disease\n* Organ or bone marrow transplant\n* History of hematologic malignancy\n* History of hepatitis C\n* HIV stage C within the last 12 months\n* Patients under legal protection\n* History of or ongoing tuberculosis\n* Chronic hepatitis B\n* Patients receiving immunosuppressive medications including patient receiving a steroid dose greater than 1mg\u002Fkg\u002Fday of prednisone equivalent for more than 1 week and patient that have been on corticosteroid for more than 3 months\n* Patient with thrombocytopenia below 50,000\u002Fmm3\n* Patient with traumatic brain and spinal injury\n* Pregnancy or breast feeding\n* Subjects with a history hypersensitivity to interferon gamma or excipient (Mannitol, Sodium succinate dibasic hexahydrate, Succinic acid, polysorbate 20), known latex hypersensitivity or other interferon\n* Hepatic cytolysis with AST\u002FALT \\> 5 times ULN (local laboratory)\n* Suspected acute pancreatitis with lipase or amylase \\> 3 times ULN (local laboratory)\n* Severe chronic renal failure (eGFR\\\u003C10 ml\u002Fmin\u002F1.73m2 CKP-EPI method)\n* Acute ECG abnormality such as myocardial infarction or any acute life-threatening ECG abnormalities (e.g: ventricular fibrillation, ventricular tachycardia…)\n* Mental state rendering the person giving consent incapable of understanding the trial\n* Patient deprived of liberty by judicial or administrative decision\n* Patient being the investigator, or any member of the team or relative of the investigator directly involved in the trial, including assistant doctors, pharmacists, nurses, trial coordinators",{"count":537,"type":22},326,[539],"PHASE3","The goal of this clinical trial is to demonstrate the benefit of a standardized immunotherapy (Interferon gamma) on the incidence of secondary infections. . It will also learn about the safety of Interferon-gamma. The main questions it aims to answer are:\n\nDoes Interferon-gamma:\n\n* reduces the Incidence of secondary infection episodes at three months\n* reduces the ICU mortality and at Day 90\n* reduces the ICU and hospital length of stay\n* induces Biological immune restoration at Day 10\n* has cost-consequence and cost-effectiveness\n\nResearchers will compare Interferon-gamma to a placebo (a look-alike substance that contains no drug) to see if Interferon-gamma works to treat sustained immunosuppression .\n\nParticipants will:\n\n* Take Interferon-Gamma or a placebo for a maximum of 5 times between day 1 and day 9\n* be monitored evety day until their ICU discharge and at day 30, 60 and 90",[542],"Sustained Immunosuppression",[544,545,546,547],"ICU","Immuno-restauration","Secondary infections","Prevention","2025-11-19",{"date":550,"type":41},"2025-11-20",{"date":552,"type":41},"2025-07-09",{"date":554,"type":22},"2028-10-09",{"name":47,"class":48},23,{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":572,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":587},"100586093","hemodynamic-evaluation-using-microcirculation-for-early-treatment-of-septic-patients-100586093","NCT06910891","Hemodynamic Evaluation Using Microcirculation for Early Treatment of Septic Patients","HEMOCAP","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Admitted to the Emergency Department for suspected Sepsis for less than 6 hours according to international Sepsis-3 definitions (high probability of infection defined by a fever greater than or equal tol to 38.3°C with a suspected infectious source + Score NEWS 2 greater than or equal to 2)\n3. Affiliated to a social security system\n4. Having agreed to participate in this study\n\nExclusion Criteria:\n\n1. Patient with arterial hypotension (SBP ≤ 100 mmHg) on admission\n2. Patient having already received a 500mL filling test over 30 minutes\n3. Patients moribund according to the investigator\n4. Pregnancy or breastfeeding\n5. Patient under guardianship, curatorship or safeguard of justice",{"count":565,"type":22},556,[25],"Despite early treatment, the deterioration and mortality of sepsis patients remains high. A possible explanation could be persistent tissue hypoperfusion, or undetected in the early phase despite the normalization of macro-hemodynamic parameters. This interventional study evaluates the impact of measuring microcirculation parameters by nurses on patient prognosis through early initiation of vascular filling.",[569,570,571],"Sepsis","Emergency Care","Microcirculation",[573,574,575,576,577,578],"microcirculation","septic patient","organ dysfunction","sepsis","peripheral perfusion index","emergency unit","2025-11-18",{"date":581,"type":41},"2025-11-21",{"date":583,"type":41},"2025-09-20",{"date":585,"type":22},"2027-03-28",{"name":47,"class":48},6,{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":597,"conditions":598,"keywords":602,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":7},"100407943","french-colorectal-esd-cohort-in-experts-centers-100407943","NCT04592003","French Colorectal ESD Cohort in Experts Centers","FECCo","Inclusion Criteria:\n\nAll patients addressed for a colorectal ESD\n\nExclusion Criteria:\n\nOpposition notified in the context of a non-opposition form after reading the information notice",{"count":596,"type":22},1200,"Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR.\n\nScientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures.\n\nA lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions.\n\nThe aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.",[599,600,601],"Cancer Colorectal","Polyps Colorectal","Endoscopic Submucosal Resection",[603,604,605],"Cancer colorectal","Polyps colorectal","Endoscopic submucosal resection","2025-09-08",{"date":608,"type":41},"2025-09-15",{"date":610,"type":41},"2020-01-01",{"date":612,"type":22},"2026-01-01",{"name":47,"class":48},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":621,"targetDuration":623,"studyType":62,"phases":4,"briefSummary":624,"conditions":625,"keywords":627,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":107},"100585627","acceptability-and-feasibility-of-simultaneous-screening-for-viral-hepatitis-b-c-and-hiv-among-drug-users-and-vulnerable-populations-in-non-conventional-structures-outside-the-walls-by-dual-screening-method-rtds-and-fibroscan-100585627","NCT06904820","Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures \"Outside the Walls\" by Dual Screening Method RTDs and FibroScan®","SCANVIRE2","Inclusion Criteria:\n\n* Adult 18 and over\n* Patient frequenting an unconventional structure \"outside the walls\" or referred by a professional in the care sector\n* Patient not opposed to research\n\nExclusion Criteria:\n\n* Age under 18\n* Patient opposed to research",{"count":622,"type":22},2300,"1 Day","The \"Scanvir\" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a \"test, treat and cure\" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.",[626],"Viral Hepatitis",[628,629,630],"HCV","eradication","marginalized patients","2025-08-13",{"date":633,"type":41},"2025-08-14",{"date":635,"type":41},"2025-06-05",{"date":637,"type":22},"2035-06-05",{"name":47,"class":48},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":646,"minAge":19,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":649,"briefSummary":650,"conditions":651,"keywords":653,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":107},"100523287","prospective-imaging-assessment-of-perineo-pelvic-statics-evolution-after-sexual-reassignment-surgery-in-mtf-transgender-patient-by-peno-scrotal-inversion-vaginoplasty-technique-transpelv-100523287","NCT06093724","Prospective Imaging Assessment of Perineo-pelvic Static's Evolution After Sexual Reassignment Surgery in MtF Transgender Patient, by Peno-scrotal Inversion Vaginoplasty Technique (TRANSPELV)","TRANSPELV","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient admitted in urology ward at Limoges' University Hospital for MtF sexual reassignment surgery by vaginoplasty\n* Patient affiliated or benefitting from a social security system\n* Patient free, informed, written and signed consent\n\nExclusion Criteria:\n\n* Patient admitted for vulvoplasty surgery\n* Patient admitted for second vaginoplasty surgical gesture\n* Contraindication of realizing an MRI","MALE",{"count":648,"type":22},50,[25],"The research consists of adding to the usual MtF transgender patient undergoing vaginoplasty care course, static and dynamic perineo-pelvic MRI before, and at 6 and 24 months. The aim is to assess perineo-pelvic static's evolution, based on the appearance of a rectocele.",[652],"Transgenderism",[654],"MtF, transgender, vaginoplasty, penoscrotal inversion, MRI","2025-07-18",{"date":657,"type":41},"2025-07-22",{"date":659,"type":41},"2023-09-08",{"date":661,"type":22},"2026-07-15",{"name":47,"class":48},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":672,"conditions":673,"keywords":675,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":107},"100511179","delta-describe-the-french-collaborative-project-100511179","NCT05936073","DELTA DESCRIBE: the French Collaborative Project","DELTADESCRIBE","Inclusion Criteria:\n\n* \\>18 years at the second step\n* HDV RNA positive patients identified at the second step\n* Patients non opposed to the collection of their data\n\nExclusion Criteria:\n\n* Opposition expressed by the patients for the collection of their data",{"count":671,"type":22},734,"Our global objective is to draw up a photograph of HDV patients over one year in metropolitan France and identify the barriers of screening and care. The investigator suspects a mismatch between HBV and HDV screening, the first step for specialized care pathway in metropolitan France.",[674],"Hepatitis D",[676,677,678,679],"HBs Ag","Delta hepatitis","Screening","Reflex testing","2025-05-24",{"date":682,"type":41},"2025-05-28",{"date":684,"type":41},"2024-01-22",{"date":686,"type":22},"2025-06-22",{"name":47,"class":48},""]